WT1 and Kaposi's sarcoma: A follow up study comparing early to late stage KS, while evaluating WT1 expression at baseline and in follow up after ART alone or in combination with directed KS treatment, may be able to better assess whether WT1 may have the potential to serve as a biomarker of treatment responses.